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CancerThe acidic nuclear phosphoproteins (ANP32A-H) are an evolutionarily conserved family of proteins with diverse
and sometimes opposing cellular functions. Here we show that the oncogenic family members ANP32C and
ANP32D are associated in complexes containing themolecular chaperone Hsp90. The oncogenic ANP32C protein
appears to be highly unstable with a rapid degradation (t1/2 N 30min) occurring upon treatment of cells with cy-
cloheximide. ANP32C was also found to be associated with oncogenic Hsp90 complexes by virtue of its ability to
interact and be immunoprecipitated by theHsp90 inhibitor PU-H71. Further studies treating cellswith theHsp90
inhibitors PU-H71 and 17-AAG showed atypical increased protein stability and prevention of ANP32C degrada-
tion compared to the Hsp90 client AKT. Cells overexpressing ANP32C or its mutant ANP32CY140H showed en-
hanced sensitivity to treatment with PU-H71 as demonstrated by CCK-8 and colony formation assays. Our
results highlight that certain malignancies with ANP32C/D overexpression or mutation might be speciﬁcally
targeted using Hsp90 inhibitors.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The ANP32 family of proteins [1,2] belongs to the superfamily of
leucine-rich repeat (LRR) containing proteins [3]. The simple domain
structure of ANP32 proteins is highly conserved and comprises a capped
LRR motif at the N-terminus [4], a central domain (amino acids ~150–
174) containing a region mediating cellular transformation [5] and a
highly acidic C terminus containing ~70% aspartic and glutamic acid
residues. The ANP32A (pp32) protein is the most characterized
familymember and has been demonstrated to act as a tumor suppressor
[6]. In contrast ANP32C (pp32r1) is oncogenic and found to be
overexpressed in poorly differentiated tumors [5,7,8]. Expression of
ANP32C also appears to be more predominant in common cancer cell
lines than in normal ﬁbroblasts [9].
Several functional mutations in ANP32C have been found to be asso-
ciated with an increase in proliferation when transfected into cells [10,
11]. We have recently determined that the increase in proliferation
upon overexpression of ANP32C or ANP32C_Y140H occurs through
the dysregulation of Chromodomain Helicase DNA-binding protein 4
(CHD4) mediated cell cycle control [12,13] and appears to be conﬁned
to p53wt cells, since ANP32C and ANP32C_Y140H expressing cells
with mutated p53were not hyperproliferative [14]. The overexpression
effects were also shown to increase resistance to the chemotherapeutic
drug FTY720 although the speciﬁc mechanism of this resistance is still
unclear [15]. Other recent studies have also suggested a possible roleuyton).for ANP32C in the cytoplasmic degradation of Human antigen R (HuR)
in oral carcinoma cell lines [9]. In contrast however we have not ob-
served any interaction of overexpressed ANP32C with HuR in kidney
cancer (ACHN) or cervical carcinoma (HeLa) cell lines suggesting that
some ANP32C functional differences may occur between different can-
cer cell types [15].
In thisworkwe sought to further explore the interactomeof ANP32C
and identiﬁedHsp90 as an ANP32C interacting protein. Hsp90 is an evo-
lutionary conserved protein chaperone and represents one of the most
highly expressed cellular proteins. The function of Hsp90 is essential
for maintaining proteome homeostasis through the control of correct
folding, stability and functional activity, intracellular allocation and pro-
tein turnover under normal and stress-inducing conditions. Hsp90 is an
ATPase with working cycle that includes multiple conformational
changes triggered by ATP binding and hydrolysis as well as successive
interactions with different partners, so-called “co-chaperones” (e.g.
Hsp70, HOP, Cdc37, p23) [16]. A subset of cellular proteins depending
on HSP90's chaperoning activity and usually referred as ‘clients’ ac-
counts for 10–30% of the proteome [17,18]. Kinases, E3 ligases and tran-
scription factors represent major classes among these Hsp90 client
proteins [19]. Many of these client proteins play key roles as effectors
in signal transduction pathways regulating cellular proliferation, cell
cycle control, division, DNA-damage response and apoptosis. They are
also when mutated or overexpressed often found to be involved in ma-
lignant transformation (i.e., p53, Erb2, EGFR, v/c-Src, AKT, Raf-1) [20].
The ability to protect mutated, destabilized or alternately expressed
proteins confers a balancing role onHsp90 that can promote the activity
of certain oncoproteins facilitating cancer cell survival and tumor
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regulation in tumors in comparison to normal tissues [22,23], empha-
sizes the importance of Hsp90 for tumor cell growth and highlights
Hsp90 as an attractive target for cancer treatment. The inhibition of
Hsp90 makes it possible to affect a number of oncogenic pathways
that are known to be under control of the chaperone. Hsp90 foundwith-
in tumor cells has been suggested to be composed of two distinct pools;
Hsp90 that participates in formation of large heterogenous protein com-
plexes that are especially abundant in oncogenic conditions and
uncomplexedHsp90 that can be found in all cells, regardless of their on-
cogenicity [24]. This original work was however refuted in subsequent
work by another group [25], however certain speciﬁc and potentially
“oncogenic” Hsp90 complexes do exhibit higher afﬁnity to certain
Hsp90 inhibitors, in particular PU-H71 [26,27].
Many small molecules have now been discovered and chemically
synthesized to target Hsp90 in cancer. Almost all Hsp90 inhibitors cur-
rently undergoing clinical investigation block the chaperone ATPase
function, leading to degradation of the oncogenic client and antitumor
activity [28,29]. Of these with the geldanamycin derivative 17-AAG is
among those that have been tested in clinical studies. The promising ef-
fectiveness of Hsp90 inhibitors in different malignancies together with
growing body of evidence on Hsp90's biology keeps Hsp90 in the
focus of researchers' attention and makes Hsp90 inhibition a highly at-
tractive therapeutic strategy for cancer treatment. In this work we de-
scribe for the ﬁrst time the association between Hsp90 and the
oncogenic ANP32 family members ANP32C and ANP32D and the effect
that this has on the efﬁcacy of Hsp90 inhibitors.2. Materials and methods
2.1. Lentiviral constructs for ANP32 family proteins
The ANP32A, B, D and E full-length genes were ampliﬁed by PCR
from full-length cDNA clones (Source Biosciences lifescience). The frag-
ments were then ﬁrst cloned as previously described for the ANP32C
gene into the pCDNA-V5-His-TOPO vector (Invitrogen) before
subcloning into the pRRL.PPT.SFFV.mcs.pre vector [14].2.2. Cell culture and lentiviral transduction
ACHN cells (DSMZ) were grown at 37 °C in a 5% CO2-humidiﬁed
atmosphere in Dulbecco's modiﬁed Eagle's medium (DMEM)
supplemented with 50 U/ml penicillin, 50 μg/ml streptomycin,
2 mM L-glutamine, 1% NEAA, 1 mM Sodium Pyruvate and 10% fetal bo-
vine serum (FBS). HeLa and HEK293T cells were grown in DMEM
supplemented with; 50 U/ml penicillin, 50 μg/ml streptomycin,
2 mM L-glutamine. Lentivirus was produced in HEK293T cells using
standard protocols and ACHN or HeLa cells were transduced as previ-
ously described [14].2.3. Fractionation of ANP32C fromoverexpressing cell lines by size exclusion
chromatography (SEC)
For “Native” fractionation of lysates HeLa cells overexpressing
ANP32C or ACP32CY140H were grown in T150 ﬂasks until ~90%
conﬂuency. Cells were then washed 3 times with PBS before being
scraped from the ﬂask surface in PBS containing 1000 U benzonase.
Cells were then mechanically lysed by repeatedly passing the cell sus-
pension through a ﬁne 27 gauge needle. The cell lysate was then centri-
fuged at 13,000 rpm for 10 min to remove cell debris and the
supernatant loaded onto a superdex 200 16/60 gel ﬁltration column
equilibrated in PBS, collecting 0.5 ml fractions. The elution proﬁle was
compared to standards of Blue Dextran (Mw ~2,000,000 Da), Rabbit
IgG (Mw ~150,000 Da) and Bovine serum Albumin (Mw ~66,000 Da).2.4. Cross-linking and immunoprecipitation of ANP32C from
overexpressing cell lines
The cell permeable and thiol-cleavable crosslinker Dithiobis-
succinimidyl propionate (DSP) (Thermo Fisher) was used according to
the protocol of Smith et al. [30] with minor modiﬁcations. Cells were
crosslinked in 2 mM DSP for 30 min at room temperature and lysed in
NP-40 buffer containing protease inhibitors cocktail (Roche) and
Benzonase (Merck).
2.5. Peptide mass ﬁngerprinting
The gel bands were cut into small pieces, de-stained with acetoni-
trile and washed repeatedly (8 M urea/ 0.4 M NH4HCO3). Samples
were then reduced with dithiothreitol for 30min at 55 °C and alkylated
with iodoacetamide for 15min at room temperature in the dark. Subse-
quently the gel pieces were washed twice and shrunken with acetoni-
trile. The gel pieces were then covered with mass-spec grade trypsin
(Serva, porcine) in cleavage buffer (2 M urea/0.1 M NH4HCO3). The di-
gest was performed at 37 °C overnight. From each sample 1 μl of the su-
pernatant after digest was used for the MALDI-MS measurement. The
MALDI-MS data were used for a database search with the software
Mascot (Matrix Science) using the SwissProt database, species:
human. Peptide mass tolerance was set to 100 ppm.
2.6. Co-immunoprecipitation
For co-immunoprecipitation (Co-IP) experiments cells were lysed
on ice by scraping and 30 min incubation in lysis buffer containing 1%
NP40, protease inhibitors cocktail (Roche) and Benzonase (Merck). In
some experiments 20 mM sodium molybdate was added to the lysis
buffer. Protein quantitationwas performed using a BCA assay (Uptima).
Lysates were precleared with protein A sepharose (GE Healthcare)
before a total of 1,5-3,5 mg protein was immunoprecipitated by anti-
V5 tag (Serotech, MCA1360) antibody pre-immobilized on protein A
beads. Beads were then washed with lysis buffer and PBS or phosphate
buffer (pH 7,4) with high salt (0,5 M NaCl) and/or 20 mM sodium mo-
lybdate where necessary. Proteins were eluted in loading dye and re-
solved on 4–20% SDS-PAGE gels (Invitrogen) and analyzed by western
blotting with anti-Hsp90 (Abcam, ab178854) or anti-Hsp70 (Thermo
Scientiﬁc, MA1-90504) antibodies.
Co-IP for detection of the interaction between ANP32CY140H and
Hsp70 was preceded by crosslinking of anti-V5 tag antibody to the
beads utilizing DMP (dimethyl-pimelimidate, Thermo Fisher) cross-
linker.
For serial IPs a portion of HeLa C lysate with 250 μg of total protein
(prepared as for a standard IP) was incubated with anti-V5 or anti-
Hsp90 antibody-coupled beads in 4 successive steps. Equal aliquots of
the remaining supernatant were collected after each step and analyzed
by western blotting with anti-V5 tag or anti-Hsp90 antibody.
2.7. Cycloheximide chase assay
HeLa C/YH cells were plated at a density of 3 × 105 (or 2 × 105) cells
perwell of 6-well plate 16 h before treatmentwith 50 μg/ml CHX (0.5 h,
1 h, 2 h, 3 h) or 0.05% DMSO (3 h) as a vehicle control. ACHNWT-D cells
were treated with 50 μg/ml CHX or 0.05% DMSO as a vehicle control for
3 h. Cells were collected by scraping in RIPA buffer and lysed for 30min
on ice. Sampleswere resolved on 4–20% SDS-PAGE gels and analyzed by
western blotting with anti-V5 tag antibody.
For combined CHX and PU-H71 (Cayman Chemicals) treatment
HeLa C/YH cells were plated as described above and treated ﬁrst for
8 h (or 24 h) with 1 μM PU-H71 and then with both 1 μM PU-H71 and
5 μg/ml CHX for 0.5 and 1 h. Cells were lysed as described before.
For the Co-IP with newly translated ANP32CY140H HeLa C/YH cells
at 80% conﬂuence were treated with 50 μg/ml CHX for 3 h. After the
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washed with PBS and fresh media was used. Cells were incubated in
the fresh media for 30 min. Lysis was performed in a standard for IP
way.
2.8. Chemical precipitation with PU-H71-conjugated beads
Chemical precipitation experiments with PU-H71-conjugated beads
on lysates of HeLaWT, HeLa C and HeLa YH cells were performed as de-
scribed by Taldone et al. [31]. PU-H71 coupled beads were generously
donated by Prof. Gabriella Chiosis (Memorial Sloan Kettering Cancer
centre, USA).
2.9. Western blotting
The transfer was performed using iBlot Dry Blotting System
(Invitrogen). After transfer a polyvinylidene diﬂuoride (PVDF) mem-
brane was blocked for 1 h in 5% low fat milk powder in PBST. Themem-
brane was then incubated overnight at 4 °C with primary antibodies.
The blot was then washed 3 times with PBST followed by incubation
with 1:2500 dilution of rabbit-anti-mouse-HRP (DAKO) or goat-anti-
rabbit-HRP (DAKO) conjugated secondary antibody for 1 h at room tem-
perature. Following 3washeswith PBST detectionwas performed by in-
cubating the blot directly with Clarity western ECL substrate (Bio-Rad)
and measured on a MultiImage II chemiluminescence imaging system
(Alpha Innotech).
2.10. CCK-8 assay
CCK-8 assay is a colorimetric method for the determination of the
number of viable cells in cell proliferation and cytotoxicity studies. It uti-
lizes WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt] that gets reduced
by dehydrogenases in cells to give an orange colored soluble product
WST-8-formazan. The amount of the formazan dye generated by dehy-
drogenases in cells is directly proportional to the number of living cells
and can be measured spectrophotometrically at 450 nm.
For the CCK-8 assay cells were plated in 96-well plates at 3000 per
well ~36 h before treatment. Treatment with different concentrations
(50, 100, 125, 250, 500, 750, 1000 nM) of PU-H71 lasted for 30 h before
CCK-8 reagent was added for 1 h and colorimetric reaction was mea-
sured on Synergy 2 Microplate Reader (BioTek).
2.11. Colony growth assay
Cells were plated in 6-well plates at a density of 3000 cells per well.
After 24 h cells were treated with 50 nM or 1 μM PU-H71 for 30 h. 0.1%
DMSOwas used as a vehicle control. After the incubationwith drug cells
were washed with PBS and then grown in fresh media with regular
media exchange until colonies were visible. The plates were ﬁxed and
stained with methylene blue solution in 50% methanol.
2.12. Cell treatment with PU-H71 and 17-AAG for WB, time-course and
Co-IP
Cells were plated out one day before treatment at a concentration to
reach 70–80% conﬂuence at the moment of treatment. Treatment was
performedwith 1 μMPU-H71 and 1 μM17-AAG for 24 h. Cells were col-
lected by scraping in RIPA buffer and lysed for 30 min on ice. Samples
were resolved on 4–20% SDS-PAGE gels and analyzed by western blot-
ting with anti-V5, Hsp90, Hsp70, GAPDH (Santa Cruz, 0411 sc-47724)
and pan-AKT (Cell Signaling, 40D4 #2920) antibodies.
PU-H71 time-course was performed on HeLa C/YH cells plated at a
density of 3 × 105 cells per well of 6-well plate 16 h before treatment.
1 μM PU-H71 was added for 0.5 h, 1 h, 1.5 h, 3 h, 5 h, 8 h or 24 h. 0.1%DMSO served as a vehicle control. Cells were lysed as described
previously.
For the Co-IP HeLa C/YH cells at 80% conﬂuence were treated with
1 μM PU-H71 or DMSO (0.1%) as a vehicle control for 24 h. Cell lysis
was performed in a standard for IP way.
3. Results
HeLa cells ectopically expressing the ANP32C protein or its mutant
ANP32C_Y140H were generated by lentiviral transduction as described
in theMaterials andmethods and are subsequently referred to asHeLa C
and HeLa YH in the text.
3.1. ANP32C is found in high molecular weight cytoplasmic complexes
Lysates of native ANP32C protein complexes were prepared by
resuspending cells in PBS containing protease inhibitors and subjecting
samples to mechanical lysis by repeatedly passing the lysate through a
small gauge needle. The resulting native protein complexes were then
fractionated by size/shape using size exclusion chromatography (SEC)
with collection of sequential fractions. Protein standards were analyzed
using the same SEC method to identify the approximate molecular
weight range across each fraction. ANP32C containing fractions were
identiﬁed via western blotting using an anti-V5 antibody and illustrated
that ectopically expressed ANP32C exists in a large range of highmolec-
ular weight protein complexes (Fig. 1a).
To stabilize these ANP32C containing complexes we utilized the Re-
versible Cross-Link ImmunoPrecipitation (ReCLIP) approach using the
cell permeable and thiol-cleavable crosslinker Dithiobis-succinimidyl
propionate (DSP) [30]. Western blotting of cell lysates from HeLa C or
HeLa YH cells treated with DSP was compared under reducing and
non-reducing conditions. In non-reducing conditions the stabilization
of several highmolecularweight complexes ~90 and ~160 kDa contain-
ing ANP32C could be achieved (Fig. 1b).
3.2. Mass spectrometry identiﬁcation of proteins in complexes containing
ANP32C
To isolate intact ANP32C containing complexes cells were again
treated with DSP and subjected to immunoprecipitation using
protein-A beads coupled with anti-V5 antibody. Comparison of control
lysates and ANP32C expressing lysates, by SDS PAGE under reducing
conditions, illustrated several speciﬁc protein bands which were ex-
cised from the gel and subjected to peptide mass ﬁngerprinting
(Fig. 1c). A number of proteins were identiﬁed from these bands includ-
ing Heat shock protein 90A/B, Tubulin, Heat shock cognate 71 kDa pro-
tein and Heat shock 70 kDa protein 1A/1B, full details are provided in
Table 1 and Supplementary Fig. 1.
3.3. Overexpression of ANP32C does not modulate Hsp90 or Hsp70 levels
We ﬁrst sought to determine if our cell lines expressing ANP32C/
Y140H showed increased levels of Heat shock proteins. Western blot-
ting demonstrated consistent levels of both Hsp90 and Hsp70 in wild
type and expressing cell lines (Fig. 2a).
3.4. Conﬁrmation of ANP32C in complexes containing Hsp90 and Hsp70
To conﬁrm the presence of ANP32C in Hsp90 or Hsp70 containing
complexes we performed co-immunoprecipitation experiments on un-
treated cell lysates. The ANP32C protein was pulled downwith protein-
A beads coupled with anti-V5 antibody and washed extensively before
blotting with anti-Hsp90 or anti-Hsp70. As can be seen in Fig. 2b and
Supplementary Fig. 2, ANP32C and ANP32C_Y140H co-precipitated
with large amounts of Hsp90. Likewise co-immunoprecipitation of
Hsp70 with ANP32C/Y140H could also be observed (Fig. 2c).
Fig. 1.ANP32C is found in highmolecularweight cytoplasmic complexes: Size exclusion chromatography of HeLa YH expressing lysates and analysis of fractions bywestern blotwith anti-
V5 antibody demonstrates a broad elution proﬁle from 2000 to 60 kDa and is eluted as two major peaks. b) Crosslinking of ANP32C/Y140H proteins using the reversible crosslinker DSP:
Lysates from cells treatedwith DSPwere compared under reducing (R) and non-reducing (NR) conditions before western blotting with anti-V5 antibody. Cross-linked complexes are ob-
servedwhich resolve at ~90 and 160 kDa. c)Mass spectrometry identiﬁcation of proteins in complexes containing ANP32C: Immunoprecipitated cross-linked complexeswere isolated and
resolved by standard SDS PAGE. Compared to HeLa cell lysates cross-linked HeLa YH lysates demonstrated additionally bound proteins. Regions 1–4 were excised and identiﬁed by mass
spectrometry (see Table 1).
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(SEC)with collection of sequential fractionswas also repeated and frac-
tions evaluated by western blotting for ANP32C/Y140H and Hsp90. As
can be seen in Supplementary Fig. 3 signiﬁcant co-elution of ANP32C/
Y140H and Hsp90 could be observed in SEC fractions, however we
could also demonstrate that not all ANP32C protein is complexed with
Hsp90 through sequential immunoprecipitation of V5 tagged ANP32C
and blotting Hsp90 in the remaining supernatant (Supplementary
Fig. 4). The reverse experiment also showed that immunoprecipitation
of all Hsp90 was not sufﬁcient to deplete all V5 tagged ANP32C from
the remaining supernatant (Supplementary Fig. 4).Table 1
Peptide mass ﬁngerprinting.
Protein band Identiﬁed proteins Mascot
(Protein score)
Sequence coverage
Band-1 HS90A_HUMAN
HS90B_HUMAN
149
272
38%
46%
Band-2 HSP7C_HUMAN
HSP71_HUMAN
175
62
39%
20%
Band-3 TBB5_HUMAN
TBA1B_HUMAN
TBB4B_HUMAN
TBB2A_HUMAN
TBB4A_HUMAN
TBB3_HUMAN
TBA1A_HUMAN
TBA1C_HUMAN
TBA3C_HUMAN
153
94
141
131
108
73
67
67
51
56%
50%
54%
52%
48%
28%
43%
43%
38%
Band-4 ND ND ND
ND (not determined).3.5. ANP32C behaves as a client of Hsp90
As discussed in the Introduction theHsp90 chaperone forms interac-
tions with both co-chaperone molecules and client proteins many of
which are listed in the Hsp90 database (http://www.picard.ch/
downloads/downloads.htm). These interactions can be distinguished
by co-immunoprecipitation under speciﬁc chemical conditions
namely the presence of molybdate ions to stabilize the Hsp90:client/
co-chaperone complexes and high salt washes to remove co-
chaperone molecules since molybdate characteristically enforces salt
resistance of Hsp90:client complexes [32–34]. We therefore performed
immunoprecipitation experiments to determine if ANP32C behaves as a
co-chaperone or client protein. We observed that high salt washes had
little effect, however the presence of molybdate ions signiﬁcantly en-
hanced the stability of ANP32C/Y140H:Hsp90 containing complexes
suggesting that ANP32C is a newly identiﬁed client protein of Hsp90
(Fig. 2d).3.6. ANP32C is rapidly degraded by the proteasome
One of the important functions of Hsp90 chaperoning is to mediate
the degradation of its various client substrates through the proteasomal
degradationmachinery.We therefore performed experiments using the
protein translation inhibitor cycloheximide and proteasome inhibitor
MG132 to determine the stability of ANP32C proteins. As depicted in
Fig. 3a–b, ANP32C and ANP32C/Y140H proteins were shown to be ex-
tremely unstable and N50% of the protein was degraded within
30 min. In contrast treatment with the proteasomal inhibitor MG132
clearly enhanced the stability of ANP32C and its mutant proteins
Fig. 2. a) Overexpression of ANP32C and ANP32C_Y140H does not change levels of Hsp90 and Hsp70:Western blot analysis to detect expression of Hsp90 and Hsp70 was performed on
lysates of HeLa cells expressing V5-tagged ANP32C and ANP32C_Y140H cells (HeLa C and HeLa YH cells respectively) in comparison to wild type HeLa cells. V5 blot shows expression of
ANP32C/Y140H. GAPDH served as loading control. b) Interaction of ANP32C/Y140H with Hsp90: Co-immunoprecipitation (Co-IP) was performed with anti-V5 antibody to capture V5-
taggedANP32C orANP32C_Y140Hproteins expressed inHeLa C andHeLaYHcells and blottedwith antibody against Hsp90.Wild typeHeLa cells servedas a control. Representative results
are shown, including V5 blot of Co-IP samples and Hsp90 input. c) Interaction of ANP32C/Y140H with Hsp70: Co-IP was performedwith anti-V5 antibody to capture V5-tagged ANP32C/
Y140Hproteins fromHeLa C andHeLa YH cells and blottedwith antibody against Hsp70.Wild type HeLa cells served as a control. Representative results are shown, including V5blot of Co-
IP samples and Hsp70 input. d) Sodiummolybdate stabilizes interaction of ANP32C/Y140Hwith Hsp90 under high salt conditions: Co-IP was performedwith anti-V5 antibody to capture
V5-tagged ANP32C/Y140H proteins from HeLa C and HeLa YH cells and blotted with antibody against Hsp90. Lysates for each cell type were prepared either with 20mM sodiummolyb-
date (3, 4, 7, 8) orwithout this agent (1, 2, 5, 6). Co-IP samples of regular or sodiummolybdate containing lysateswerewashed eitherwith low salt (137mMNaCl) buffer (1, 3, 5, 7) or high
salt (500 mM NaCl) buffer (2, 4, 6, 8). Representative results are shown, including V5 blot of Co-IP samples and Hsp90 input (M corresponds to molybdate).
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(Supplementary Fig. 5a,b).3.7. Newly translated ANP32C protein is rapidly associated with Hsp90
To demonstrate that reduced levels of ANP32C protein are also read-
ily bound by Hsp90 complexes we performed a pulse-chase immuno-
precipitation experiment. First translation of ANP32C mRNA was
inhibited by cycloheximide for 3 h, as shown previously in Fig. 3b–c,
to be sufﬁcient to allow complete degradation of ANP32C/Y140H pro-
teins. Cells were then left to recover for 30 min before immunoprecipi-
tation. These newly translated proteins were again shown to be readily
bound by Hsp90 (Fig. 3c).3.8. Only ANP32C and ANP32D are novel clients of Hsp90
ANP32C belongs to a family of proteins all sharing high sequence
identity and in some cases overlapping functional roles in cellular pro-
cesses. The observation that ANP32C formed complexes containing
Hsp90 and behaves as a client protein therefore prompted us to deter-
mine if other ANP32 family members were also clients of Hsp90. Co-
immunoprecipitation experiments on cell lysates from ACHN cells ex-
pressing ANP32A, B, C, C-YH, D and E were performed in parallel. As
can be seen from Fig. 3d, only ANP32C and ANP32D proteins were
found to co-precipitate in complexes containing Hsp90. Similar to
ANP32C the presence of molybdate ions signiﬁcantly enhanced the
stability of ANP32D:Hsp90 containing complexes that also showed
high-salt resistance suggesting that ANP32D is also a client protein of
Hsp90 (Supplementary Fig. 6).We then repeated cycloheximide inhibition studies on cell lines ex-
pressing all the ANP32 family members. In these experiments we ob-
served that only the oncogenic family members ANP32C and ANP32D
were intrinsically unstable and rapidly degraded, while the other family
members showed no sign of degradation (Fig. 3e).
3.9. ANP32C is co-precipitated with “oncogenic” Hsp90 complexes
Proteomics data has shown that multiple oncoproteins involved in
tumor proliferation, survival and invasive potential are found in com-
plex with PU-H71-bound Hsp90 [26]. We performed chemical precipi-
tation using PU-H71 coupled beads (generously donated by Prof.
Gabriella Chiosis, Memorial Sloan Kettering Cancer centre). In control
HeLa cell lysates Hsp90 could be efﬁciently pulled-down, while in
ANP32C/Y140H expressing lysates complexes containing ANP32C/
Y140H:Hsp90 were pulled down (Fig. 4a).
3.10. Atypical effects of PU-H71 inhibition on ANP32C degradation
It has been demonstrated that many clients of Hsp90 are degraded
upon Hsp90 inhibition. To examine if this holds true for ANP32C/
Y140H we performed a time course experiment treating HeLa C/YH
with PU-H71 for different time periods (Fig. 4b). This experiment
showed a complex time-dependent response of ANP32C/Y140Hprotein
level to treatment with PU-H71 with degradation within ﬁrst 1.5 h of
treatment followed by a gradual increase of protein levels. The observed
degradation of ANP32C/Y140H supports the claim that ANP32C and its
mutant are novel clients of Hsp90 folding machinery. The ANP32C/
Y140H degradation is characterized by fast kinetics with substantial
drop in protein level already after 1.5 h of PU-H71 treatment and
Fig. 3. a) Cycloheximide (CHX) chase assay to determine stability of ANP32 family members: ACHN C cells were treated with CHX (50 μg/ml) for indicated periods of time and western
blotting was performed. Treatment with DMSO as a vehicle control (0.05%) lasted 3 h. b) Cycloheximide chase assay to determine stability of ANP32 familymembers: ACHN YH cells were
treated with CHX (50 μg/ml) for indicated periods of time and western blotting was performed. Treatment with DMSO as a vehicle control (0.05%) lasted 3 h. c) Newly synthesized
ANP32C/Y140H interact with Hsp90: Co-IP was performed with anti-V5 antibody to capture V5-tagged ANP32C/Y140H proteins produced by HeLa C or HeLa YH cells within 0.5 h
after 3 h-treatment with 50 μg/ml CHX and blotted with antibody against Hsp90. Wild type HeLa cells served as a control. Representative results are shown, including V5 blot of Co-IP
samples and inputs for Hsp90 and V5. d) Studying of the interaction of ANP32 family members with Hsp90: Co-IP was performed with anti-V5 antibody to capture V5-tagged proteins
of ANP32 family (ANP32A, ANP32B, ANP32C, ANP32C140YH, ANP32D, ANP32E) ectopically expressed in ACHN cells (ACHN A, ACHN B, ACHN C, ACHN YH, ACHN D and ACHN E
respectively) and blotted with antibody against Hsp90. Wild type ACHN cells served as a control. Representative results are shown, including V5 blot of Co-IP samples and Hsp90
input. e) Cycloheximide chase assay to determine stability of ANP32 family members: ACHN A, B, C, YH, D and E cells were treated with CHX (50 μg/ml) or DMSO as a vehicle control
(0.05%) for 3 h and western blotting was performed.
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inhibition. Starting from 3 h of treatment with PU-H71 we observed a
“late-response” with gradually increased ANP32C/Y140H levels that is
a nontrivial effect of Hsp90 inhibition on its clients. To further study
this phenomenon of ANP32C/Y140H stabilization under conditions of
prolonged presence of Hsp90 inhibitor PU-H71 we utilized another
well-studied Hsp90 inhibitor 17-AAG. We treated cells with PU-H71
or 17-AAG for 24 h to monitor the levels of Hsp90, Hsp70, AKT and
ANP32C and its mutant proteins compared to untreated controls
(Fig. 4c). While the level of Hsp90 remained constant in treated or un-
treated samples the levels of Hsp70 are signiﬁcantly upregulated as
has been previously described [35]. As a positive control we performed
westernblotting of thewell characterizedHsp90 clientAKT and demon-
strated signiﬁcant degradation of AKT protein upon 24 h treatmentwith
either 17-AAG or PU-H71. In contrastmoderate increases in the levels of
ANP32C/Y140H could be observed in treated samples (Fig. 4c), these
quantiﬁed over multiple experiments (n= 5) were shown to be signif-
icant (p b 0.05) for HeLa C treated cells and HeLa YH cells treated with
17-AAG, but not HeLa YH treated with PU-H71 (SupplementaryFig. 7). These relatively small increases could however be further
enhanced by combining a PU-H71 or 17-AAG pretreatment with a
short-term cycloheximide incubation (Fig. 4d and Supplementary
Fig. 8). Using equal amounts of PU-H71 treated and untreated
samples we also compared the amount of Hsp90 that could be co-
immunoprecipitated with ANP32C/Y140H proteins and observed that
after prolonged incubation of cells with PU-H71 cells could co-
precipitate with signiﬁcantly more Hsp90 (Fig. 4e). This further high-
lights that long-term Hsp90 inhibition also inhibits degradation of
ANP32C.
To better understand the role of Hsp90 and its inhibition in degrada-
tion of ANP32C/Y140H we extended our studies with the proteasome
inhibitor MG132. We found that combined treatment with MG132
and PU-H71 did not additionally affect the stabilization of ANP32C/
Y140H. This implies that the stabilizing effect of PU-H71 on ANP32C/
Y140H is exerted via the inhibition of proteasomal degradation and
therefore supports the idea that apart from assistance in folding,
Hsp90 can mediate proteasomal degradation of ANP32C and its mutant
(Supplementary Fig. 5c).
Fig. 4. a) PU-H71 precipitation of Hsp90 complexes with ANP32C or ANP32C_Y140H: Chemical precipitation was performed with PU-H71-conjugated or control beads on lysates from
HeLa C and HeLa YH cells and blotted with antibody against V5-tag. Wild type HeLa cells served as a control. Representative results are shown, including Hsp90 blot of chemical precip-
itation samples aswell asHsp90 and V5 input. b) PU-H71 time course: HeLa C/YH cellswere treatedwith 1 μMPU-H71 for indicated periods of time orDMSO(0.1%) as a vehicle control for
24 h. ANP32C/Y140H protein levels were analyzed by western blotting with anti-V5 tag antibody. β-Actin served as a loading control. c) Hsp90 inhibitors PU-H71 and 17-AAG cause an
increase in ANP32C/Y140H level: Western blot analysis to detect expression of Hsp90, Hsp70, AKT and ANP32C/Y140H was performed on lysates of wild type HeLa (1,4,7,10), HeLa C
(2,5,8,11) and HeLa YH (3,6,9,12) cells treated with 1 μM PU-H71/17-AAG or DMSO (0.1%) as a vehicle control for 24 h. V5 blot shows expression of ANP32C/Y140H. GAPDH served as
a loading control. d) Combined treatment with PU-H71 and CHX: HeLa YH cells were pretreated with 1 μM PU-H71 or DMSO (0.1%) as a control for 8 or 24 h before CHX at 5 μg/ml
was added. Treatment with CHX lasted 0.5 or 1 h. Levels of ANP32C_Y140H and pan-AKT were analyzed by western blotting with anti-V5 and anti-pan-AKT antibodies respectively.
GAPDH served as a loading control. e) PU-H71 stabilizes complexes of ANP32C/Y140H:Hsp90: HeLa C and HeLa YH cells were treated with 1 μM PU-H71 or DMSO (0.01%) as a vehicle
control for 24 h. Co-IP was performed with anti-V5 antibody to capture V5-tagged ANP32C/Y140H proteins from PU-H71 or DMSO-treated HeLa C or HeLa YH cells and blotted with an-
tibody against Hsp90. Representative results are shown, including V5 blot of Co-IP samples and Hsp90 input.
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To determine the dose dependent effect of PU-H71 treatment
(50–1000 nM) on cell viability we carried out CCK-8 proliferation
and colony formation assays. Cells overexpressing ANP32C or
ANP32C_Y140H were visibly more sensitive than wild-type HeLa
cells and showed more signs of apoptosis; detachment, shrinkage and
rounding. These effects were clearly evident in CCK-8 measurements
of cell proliferation (Fig. 5a). Additional colony formation assays
were carried out at two concentrations (50 nM and 1 μM PU-H71) forthe three cell lines as shown in Fig. 5b. At these concentrations no colo-
nies could be observed in ANP32C/Y140H expressing cells treated with
1 μM PU-H71, while wild-type cells retained a strong colony forming
capacity.
4. Discussion
Our aims for this work were to explore in more detail the func-
tion of the ANP32C protein by identifying the proteins that interact
with it and help mediate the proliferative cellular phenotype that
Fig. 5.HeLa C and HeLa YH cells showed enhanced sensitivity to treatmentwith PU-H71: a)Wild typeHeLa, HeLa C andHeLa YHwere treatedwith indicated concentrations of PU-H71 for
30 h. Cell viability was measured by colorimetric CCK-8 assay. b) Wild type HeLa, HeLa C and HeLa YH cells were pre-treated with PU-H71 at 50 nM and 1 μM concentrations or DMSO
(0.1%) as a vehicle control for 30 h and left for recovery and colony formation before ﬁxation and staining with methylene blue.
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described ANP32C interacting protein so far is the Human antigen
R (HuR) in oral carcinoma cell lines [9] and although we have failed
to reproduce this interaction in either cervical (HeLa) or kidney
(ACHN) cancer cell lines [15] however it is possible that other cell
speciﬁc factors such as speciﬁc mRNAs might be required to mediate
this interaction.
Here we show for the ﬁrst time that two members of the ANP32
family (ANP32C and ANP32D) are predominantly associated in high
molecular weight complexes containing the cellular chaperones
Hsp90 andHsp70. The clients of Hsp90 are functionally and structurally
diverse comprisingmany different classes of proteins such as transcrip-
tion factors, hormone receptors, ubiquitin ligases and kinases, however
they all require Hsp90 for proper folding and stabilization in order to
gain functional activity [21]. We have clearly demonstrated that
ANP32C and ANP32D show the characteristics of Hsp90 client proteins
as their interaction is stabilized by molybdate ions and unperturbed
under high salt washing conditions (Fig. 2c and Supplementary Fig. 6).
The criterion of molybdate stabilization is sometimes not absolutely
speciﬁc to clients. The interaction of Hsp90 with its co-chaperone
Aha1 has been also shown to be strengthened by molybdate ions [34]
however onlymolybdate-frozenHsp90:client complexes seem to be re-
sistant to high salt treatment [32–34].
The ANP32C and ANP32D proteins are not unique LRR-containing
clients of Hsp90 since Leucine-Rich Repeat Kinase 2 (LRRK-2) [36],
nucleotide-binding domain and leucine-rich repeat (NLR) containing
proteins [37] and Scribble (Scrib) [38] have all been described as exam-
ples of LLR-containing proteins that require Hsp90 chaperoning activity.
The ANP32C/D LRR-domain appears to be the region responsible for
interaction with Hsp90 as ANP32D lacks the extended C-terminal re-
gion that is found in other ANP32 familymembers (see Sequence Align-
ment, Supplementary Fig. 9). At the same time the LRR-domain of other
ANP32 family members despite high sequence similarity does not con-
fer any association with Hsp90 since only the oncogenic ANP32C and
ANP32D proteins were able to co-immunoprecipitate with Hsp90 in
our experiments andANP32A, B or Ewere not. This phenomenon of var-
iable speciﬁcity of Hsp90 toward protein within the same family has
been described for certain kinases, where it was concluded that thermal
instability but not any particular structural motif is the major determi-
nant of a Hsp90:kinase interaction [19]. In the same study a correlation
between protein half-life time and the strength of interaction with
Hsp90 was also described, where proteins having the shortest lifespan
were shown to have the strongest interaction with Hsp90. This also ap-
pears consistent with our observations that other ANP32 family pro-
teins remained inherently stable while ANP32C and ANP32D are
quickly degradedwhen translationwas blockedwith cycloheximide. In-
deed ANP32C/Y140H levels dropped to less than half of the initialamount within 0.5 h while full degradation of the proteins could be
seen after 1–2 h (Fig. 3b–d). Experiments usingMG132 to block the pro-
teasome, illustrated that the level of ANP32C/Y140H was dramatically
increased, similar to the p53 positive control (Supplementary Fig. 5a).
The ubiquitination of ANP32C/Y140Hwas also detected upon treatment
with MG132 via co-immunoprecipitation experiments using anti-V5
and anti-ubiquitin antibodies (Supplementary Fig. 5b).
Understanding the important role played by Hsp90 in both cellular
pathologies and in normal cells is critical in developing new drugs
that might be used to treat cancer and neurodegenerative diseases.
There appears to be no known sequence consensus or structural ele-
mentswithin Hsp90 client proteins that enable us to distinguish a client
from the rest of proteome [19]. Therefore to identify which proteins
constitute the Hsp90 interactome and which speciﬁc cellular pathways
are subsequently affected many groups have undertaken large scale
proteomics based studies [19,26]. From these and other individual
data an extensive list of Hsp90's client proteins and co-chaperones has
been collated by Dr. Didier Picard (http://www.picard.ch/downloads/
downloads.htm) and presumably due to their low endogenous expres-
sionANP32C or ANP32D are not foundon this list. Hsp90 inhibitor based
proteomic studies or inhibitor pull downs might also be unlikely to
identify such “rapidly degraded” proteins like ANP32C/D. Similarly de-
spite extensive screening of the Hsp90 interactome in yeast [19] certain
proteins like the ANP32 family members have no attributed yeast ho-
mologue, highlighting that inter-species comparisons are not always
applicable.
It has been suggested thatHsp90 alongwithHsp70 can participate in
both folding and degradation for the same client even under physiolog-
ical conditions [35] and we believe that this is likely to be the case
for ANP32C and ANP32D. We therefore continued to explore the
ANP32C:Hsp90 interaction by investigating the effects of Hsp90 ATP
binding site speciﬁc drugs including 17-AAG, a synthetic variant of
geldanamycin, and the purine scaffold inhibitor PU-H71. Using a bead
conjugated Hsp90 inhibitor PU-H71 we were able to readily precipitate
Hsp90 complexes containing ANP32C and its mutant (Fig. 4a). The ma-
jority ofwell-studiedHsp90 clients such asAKT and EGFR [26] or FANCA
[39] show disruption of their interaction with Hsp90 and are rapidly
degraded by the proteasome pathway upon cellular treatment with
17-AAG or PU-H71. Similarly we observed quick degradation of
ANP32C/Y140H within 1.5 h after addition of PU-H71 during time
course experiments. These effects of Hsp90 inhibition, although not
sustained, are typical for classic Hsp90 clients and is an additional
evidence for ANP32C/Y140H being an Hsp90 client (Fig. 4b). Prolonged
treatment with PU-H71 leads to the gradual accumulation of ANP32C/
Y140H due to increased resistance to proteasomal degradation
(Fig. 4c and Supplementary Fig. 5c). Treatment for 24 h with PU-H71
or 17-AAG showed moderately increased protein levels in comparison
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noprecipitate signiﬁcantly more Hsp90 from PU-H71 treated samples
than the control (Fig. 4e).
A small fraction (about 1%) of Hsp90 inhibition responsive proteome
illustrates the same (downregulation followed by upregulation over the
basal level) time-dependent pattern of quantitative changes. These re-
sults recently described in a T-cell proteome dynamics study upon
geldanamycin treatment [40] suggest that ANP32C and its mutant are
not unique in their behavior. Such a complex outcome of Hsp90 inhibi-
tionmight be interpreted as a disturbance of two independent process-
es occurring simultaneously in the cell, one responsible for ANP32C
stability and the other one performing ANP32C degradation under nor-
mal physiological conditions thus maintaining balanced steady state
level of the protein. It's important to note that the level of
ANP32C_Y140H protein ectopically expressed in our cellular models
HeLa YH and ACHN YH is reasonably higher than the level of wild
type ANP32C in HeLa C and ACHN C. The reason for that could be a
shift in balance between degradation and stabilization toward the
latter as seen in MG132 or PU-H71/17-AAG- treatment experiments
(Supplementary Figs. 5 and 7). Therefore themore stable and abundant
mutant ANP32C_Y140H is able to exert a stronger phenotype in cells
[10,14]. The increased amount of ANP32C protein after prolonged inhi-
bition of Hsp90 might be explained by Hsp90's direct action or through
indirect effects such as degradation or loss of function of an as yet un-
identiﬁed negative regulator. Indeed this has previously been observed
in the case of p53where a drop inMDM2 andMDMXproteins is accom-
panied by increased levels of p53 upon 17-AAG administration [41,42].
Another indirect effect of 17-AAG on protein abundance regardless of
its client–non-client status is the increased transcription activity of
the HSF1 transcription factor. This has been shown to be the cause of
protein upregulation for several proteins including: synapsin I,
synaptophysin, and PSD95 in neurons [43], IL-10 produced by Tregs of
mice colon mucosa [44] and chaperones with co-chaperones.
Differential protein regulation is a common response to the admin-
istration of geldanamycin or its derivatives 17-AGG and 17-DMAG. Al-
though proteomic studies have revealed that protein down-regulation
is most frequently observed, a signiﬁcant portion of the proteome com-
prised mainly of proteins involved in: protein folding, unfolded protein
response, proteasomal degradation, cytoskeletal proteins andmetabolic
enzymes is consistently up-regulated upon treatment with these drugs
[45–47]. Additionally the oncogenic signaling pathways of Hsp90 inhib-
itor treated cells have also been recently studied using more modern
stable isotope labeling by amino acids in cell culture (SILAC) techniques
and revealed a large number of oncogenes enriched after 20 h of
treatment with geldanamycin [40,48]. The most straightforward expla-
nation for the increased level of ANP32C in response to treatment
with 17-AAG/PU-H71 suggests a role for Hsp90 in its degradation. In-
deed recent studies have shown that Hsp90-dependent folding and
degradation are executed by distinct molecular complexes containing
variable levels of Hsp70, CHIP and HOP activity that make folding
predominant under normal conditions [49]. Hsp90 also actively
participates in the proteasomal degradation of selected clients [35],
including membrane proteins CYP2E1 [50], delta F508 CFTR mutant
[51], apoprotein B [52], mutated forms of lysosomal enzyme
glucocerebrosidase [53], misfolded or mutated cytosolic protein VHL
[54], and chaperone-mediated autophagy for selective degradation of
cytosolic proteins in lysosomes [55]. Interestingly, there are some re-
ports of Hsp90 clients that do not undergo degradation when Hsp90 is
inhibited with geldanamycin or PU-H71 but demonstrate subtle chang-
es in their phosphorylation status (e.g. STAT3/5) [26,47]. If ANP32C
changes its activity/modiﬁcation pattern under conditions of Hsp90 in-
hibition remains to be determined.
The treatment of ANP32C or ANP32C_Y140H overexpressing cells
also conferred sensitivity to PU-H71, as demonstrated by CCK-8 prolif-
eration and colony formation assays (Fig. 5). Modulation of drug resis-
tance appears to be a common effect of ANP32 protein expressionsince the overexpression of ANP32A protein has been shown to cause
the resistance of cells to the chemotherapeutic agent Gemcitabine
while conveying sensitivity to 5-Fluoro Uracil [56]. We have also
shown that ANP32C expression can convey enhanced resistance to the
drug FTY720 [15]. PU-H71 has been shown to induce apoptosis in
HeLa cells, as well as in melanoma, cervix, colon, liver and lung cancer
cells, but not in normal human ﬁbroblasts [57] implying that cells
with high malignant potential like the hyperproliferative HeLa C and
HeLa YH cells used in our study should display more sensitivity to
drug effects in comparison to normal cells or in our case wild type
HeLa cells.
It is generally believed that Hsp90 inhibition causes cytostatic and/or
cytotoxic effects via degradation of Hsp90 oncogenic clients. Aside from
physical depletion Hsp90 dependent oncogenes can be inactivated via
loss of function byHsp90 inhibitors, as Hsp90 promotes not only folding
and stability of its clients but also functional activation [58] and assists
in multiprotein complex formation [59]. In case of HeLa C and HeLa
YH cells, reduced viability in response to treatment with PU-H71 in
comparison to wild type HeLa cells might be explained by a number of
events with a cumulative cytostatic/cytotoxic effect. Firstly, ANP32C/
Y140H folding is compromised under conditions of Hsp90 inhibition.
Secondly, it is plausible that Hsp90 inhibition could additionally lead
to changes in modiﬁcation/activity status of mature protein or their
ability to participate in protein assemblies leading to a subsequent loss
of function. Thirdly, sinceHsp90 also plays a role in ANP32C/Y140Hdeg-
radation either directly or indirectly, its inhibitor PU-H71 in the context
of abrogated folding might lead to accumulation of the misfolded pro-
tein and formation of toxic protein aggregates. In case increased
ANP32C/Y140H retains some functional potential, communication
with downstream effectors might be prevented by PU-H71 treatment
since it eliminates multiple drivers of cell proliferation, invasive poten-
tial and pro-survival proteins that have been described for PU-H71 in
triple-negative breast cancer [60]. Which mechanisms are crucial for
the PU-H71 cytotoxic effect on HeLa C/YH cells, or whether they all
take place remains to be identiﬁed.
Interestingly Hsp90 inhibition is of particular importance for pros-
tate cancer since Hsp90 is overexpressed in prostate cancer cells com-
pared with normal prostate epithelium [61] and it regulates the
maturation and stability of many proteins that drive the development
and progression of prostate cancer, including the androgen receptor
[62]. The theory that Hsp90 inhibitors should show increased efﬁcacy
in cancers that are driven by Hsp90 client proteins, has also been sup-
ported by a number of clinical trials in breast cancer [63] and non-
small cell lung carcinoma [64]. However, despite expression of
ANP32C and ANP32D in tumors of the breast [8] and prostate [7] as
well as reported expression in oral carcinoma cells [9] it is difﬁcult to de-
termine the clinical implications of our preliminary observations on
cells treated with PU-H71 as details regarding the frequency of
ANP32C/D overexpressing tumors are not available. The diverse molec-
ular functions of ANP32 family proteins despite such close sequence
identity remains amysterious feature that requires further investigation
and it remains to be seen what true role ANP32C and ANP32D might
play in normal and malignant cells.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.06.007.
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